Protein / target

Tyrosine-protein kinase Lyn

LYNP07948Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
2
Approved medicines
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Non-membrane spanning protein tyrosine kinase activity

Primary system

Immune system

Strongest disease association

autoinflammatory disease, systemic, with vasculitis

Genetic evidence · score 0.85

Therapeutic maturity

Clinically validated target

2 approved medicines against this target

Druggability

Small molecule

Open Targets tractability · Approved Drug

Clinical development

2 approved · 7 in clinical development

30 linked trials

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents. Functions primarily as negative regulator, but can also function as activator, depending on the context. Required for the initiation of the B-cell response, but also for its down-regulation and termination. Plays an important role in the regulation of B-cell differentiation, proliferation, survival and apoptosis, and is important for immune self-tolerance. Acts downstream of several immune receptors, including the B-cell receptor, CD79A, CD79B, CD5, CD19, CD22, FCER1, FCGR2, FCGR1A, TLR2 and TLR4. Plays a role in the inflammatory response to bacterial lipopolysaccharide. Mediates the responses to cytokines and growth factors in hematopoietic progenitors, platelets, erythrocytes, and in mature myeloid cells, such as dendritic cells, neutrophils and eosinophils. Acts downstream of EPOR, KIT, MPL, the chemokine receptor CXCR4, as well as the receptors for IL3, IL5 and CSF2. Plays an important role in integrin signaling. Regulates cell proliferation, survival, differentiation, migration, adhesion, degranulation, and cytokine release. Involved in the regulation of endothelial activation, neutrophil adhesion and transendothelial migration (PubMed:36932076). Down-regulates signaling pathways by phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIM), that then serve as binding sites for phosphatases, such as PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1, that modulate signaling by dephosphorylation of kinases and their substrates. Phosphorylates LIME1 in response to CD22 activation. Phosphorylates BTK, CBL, CD5, CD19, CD72, CD79A, CD79B, CSF2RB, DOK1, HCLS1, LILRB3/PIR-B, MS4A2/FCER1B, SYK and TEC. Promotes phosphorylation of SIRPA, PTPN6/SHP-1, PTPN11/SHP-2 and INPP5D/SHIP-1. Mediates phosphorylation of the BCR-ABL fusion protein. Required for rapid phosphorylation of FER in response to FCER1 activation. Mediates KIT phosphorylation. Acts as an effector of EPOR (erythropoietin receptor) in controlling KIT expression and may play a role in erythroid differentiation during the switch between proliferation and maturation. Depending on the context, activates or inhibits several signaling cascades. Regulates phosphatidylinositol 3-kinase activity and AKT1 activation. Regulates activation of the MAP kinase signaling cascade, including activation of MAP2K1/MEK1, MAPK1/ERK2, MAPK3/ERK1, MAPK8/JNK1 and MAPK9/JNK2. Mediates activation of STAT5A and/or STAT5B. Phosphorylates LPXN on 'Tyr-72'. Kinase activity facilitates TLR4-TLR6 heterodimerization and signal initiation. Phosphorylates SCIMP on 'Tyr-107'; this enhances binding of SCIMP to TLR4, promoting the phosphorylation of TLR4, and a selective cytokine response to lipopolysaccharide in macrophages (By similarity). Phosphorylates CLNK (By similarity). Phosphorylates BCAR1/CAS and NEDD9/HEF1 (PubMed:9020138)

Subcellular location

Cell membraneNucleusCytoplasmCytoplasm, perinuclear regionGolgi apparatusMembrane
Domains and Gene Ontology detail (121)

Domains & features

SH3SH2Protein kinase

Gene Ontology

  • Cadherens junction
  • Ccytoplasm
  • Ccytoplasmic side of plasma membrane
  • Ccytosol
  • Cendocytic vesicle membrane
  • Cextracellular exosome
  • Cglutamatergic synapse
  • CGolgi apparatus
  • Cintegrin alpha2-beta1 complex
  • Clysosomal membrane
  • Cmembrane raft
  • Cmitochondrial crista

512 aa · 59 kDa · 2 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

HaemostasisUniProt · GO · ReactomeKinase signallingUniProt · GOImmune signallingUniProt · GOSynaptic signallingGOApoptosis & cell deathGOExcitatory neurotransmissionGO
View supporting evidence

Haemostasis

  • ·Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors…
  • ·platelet-derived growth factor receptor binding
  • ·platelet degranulation
  • ·regulation of platelet aggregation

Kinase signalling

  • ·Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors…
  • ·kinase activity
  • ·non-membrane spanning protein tyrosine kinase activity
  • ·phosphorylation-dependent protein binding

Immune signalling

  • ·Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors…
  • ·adaptive immune response
  • ·B cell homeostasis
  • ·B cell proliferation

Synaptic signalling

  • ·glutamatergic synapse
  • ·postsynaptic specialization, intracellular component

Apoptosis & cell death

  • ·positive regulation of dendritic cell apoptotic process
  • ·regulation of B cell apoptotic process

Excitatory neurotransmission

  • ·glutamatergic synapse
View underlying pathways (25)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

CD79ASYKBLNKCD19GP6BTKCD79BFYNVAV1SHC1LYN

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

bosutinib
ApprovedInhibitor

Tyrosine-protein kinase Lyn inhibitor

Appears in clinical studies involving breast cancer, neoplasm, chronic myelogenous leukemia, BCR-ABL1 positive, chronic myelogenous leukemia, BCR-ABL1 positive

Direct interaction with this protein · 1 of 4 recorded protein targets

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Translational evidence

Open Targets 26

Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.

Strongest genetic associations

Human genetic evidence — the most direct causal link between this target and a disease.

autoinflammatory disease, systemic, with vasculitis0.85

Genetic · overall 0.71

neoplasm0.19

Genetic · overall 0.52

Highest-confidence therapeutic associations

Diseases where a drug acting on this target has already reached clinical development.

chronic myelogenous leukemia, BCR-ABL1 positive0.95

Clinical · overall 0.60

acute lymphoblastic leukemia0.89

Clinical · overall 0.56

breast cancer0.68

Clinical · overall 0.44

lymphoid leukemia0.67

Clinical · overall 0.41

cancer0.09

Clinical · overall 0.57

Highest overall evidence

Remaining associations by Open Targets' aggregated evidence score.

neurodegenerative disease0.53

Pathway

cutaneous leishmaniasis0.46

Pathway

dengue disease0.37

Pathway

Show all associations
autoinflammatory disease, systemic, with vasculitis0.71
chronic myelogenous leukemia, BCR-ABL1 positive0.60
cancer0.57
acute lymphoblastic leukemia0.56
neurodegenerative disease0.53
neoplasm0.52
cutaneous leishmaniasis0.46
breast cancer0.44
lymphoid leukemia0.41
dengue disease0.37

Open Targets ranks 1,077 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.

Known drugs · 9 total

JNJ-26483327Phase 1
TOLIMIDONEPhase 2

Obesity · type 2 diabetes mellitus · type 2 diabetes mellitus

DASATINIB ANHYDROUSApproval

chronic myelogenous leukemia, BCR-ABL1 positive · acute lymphoblastic leukemia · chronic myelogenous leukemia, BCR-ABL1 positive

ILORASERTIBPhase 2

juvenile myelomonocytic leukemia · acute myeloid leukemia · myelodysplastic syndrome

BAFETINIBPhase 2

B-cell chronic lymphocytic leukemia · prostate cancer · leukemia

XL-228Phase 1

childhood leukemia · acute lymphoblastic leukemia · chronic myelogenous leukemia, BCR-ABL1 positive

ENMD-981693Phase 2

colorectal carcinoma · breast carcinoma · exocrine pancreatic carcinoma

BOSUTINIBApproval

breast cancer · neoplasm · chronic myelogenous leukemia, BCR-ABL1 positive

TG100-801Phase 2

macular degeneration · age-related macular degeneration

Tractability

SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyAB · GO CC high confAB · UniProt loc med confAB · Human Protein Atlas locPR · LiteraturePR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life Data

Safety liabilities

regulation of catalytic activity

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Show remaining trials (24)

ClinicalTrials.gov via the drug-target graph.

Forefront confidence

Synthesis

Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.

autoinflammatory disease, systemic, with vasculitisWell supported
0.88
agreement 0.751.00
Genetic84%Animal model17%Genetic literaturedup

Open Targets aggregate 0.71 · 2 independent evidence families · 1 not counted as duplicate

chronic myelogenous leukemia, BCR-ABL1 positiveWell supported
0.78
agreement 0.650.91
Clinical76%Animal model20%Literature4%

Open Targets aggregate 0.60 · 3 independent evidence families

neoplasmModerately supported
0.73
agreement 0.640.83
Clinical58%Genetic19%Literature13%Somatic mutation10%

Open Targets aggregate 0.52 · 4 independent evidence families

acute lymphoblastic leukemiaModerately supported
0.70
agreement 0.550.86
Clinical87%Literature13%

Open Targets aggregate 0.56 · 2 independent evidence families

breast cancerModerately supported
0.57
agreement 0.410.72
Clinical81%Literature19%

Open Targets aggregate 0.44 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.

What's happening now

4

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. Regulatory approval2026-06-12

    Approval: BOSUTINIB (ANDA209624)

    fda · regulatory · fda · via bosutinib

  2. Regulatory approval2025-05-23

    Approval: BOSUTINIB (ANDA209543)

    fda · regulatory · fda · via bosutinib

  3. New publication2020-03-03
    European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

    Leukemia · 2020 · 1,035 citations · Europe PMC · via bosutinib

  4. Regulatory approval2013-03-27

    Approval: Bosulif (EMA)

    ema · regulatory · ema · via bosutinib

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.